For over a century, scientists have tried to use the body’s own immune system to combat diseases. Today, there are FDA-approved drugs that achieve this endeavor due to innovation in precision medicine by pioneering scientists, and visionary leaders across disciplines in artificial intelligence, genomic, bioinformatics, cloud-computing, health care, biotechnology, and pharmaceutical industries. At this week’s American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, a number of companies are sharing how they are applying artificial intelligence (AI) to precision oncology.
Three-platform genetic sequencing offers hope for improved pediatric oncology diagnostics and precision medicine therapies.
Dark Daily has long predicted that multiomics will someday play an important role in clinical laboratory diagnostic medicine. Now, new research from St. Jude Children’s Research Hospital provides early evidence of that prediction coming to fruition.
More than 15 years after scientists first mapped the human genome, most diseases still cannot be predicted based on one's genes, leading researchers to explore epigenetic causes of disease. But the study of epigenetics cannot be approached the same way as genetics, so progress has been slow. Now, researchers at the USDA/ARS Children's Nutrition Research Center at Baylor College of Medicine and Texas Children's Hospital have determined a unique fraction of the genome that scientists should focus on.
A Tulane University professor's 20-year quest to develop a nonaddictive opioid painkiller has cleared another major hurdle in its early phases of laboratory testing.
The drug, known as ZH853, has shown in recent tests to not only accelerate recovery from pain better than morphine, but also to sidestep a key problem with morphine and other prescription painkillers derived from the opium poppy.
A new blood test could help predict whether women with breast cancer will respond to treatment before it begins.
Scientists at the Institute of Cancer Research in London said the “liquid biopsy” can detect genetic changes in the tumours of patients and indicate if they are less likely to respond to a new targeted drug.
Diagnosing von Willebrand disease (VWD) is challenging due to its highly variable clinical presentation, including various types of bleeding such as gastrointestinal bleeding, gingival bleeding, severe menstrual bleeding, and epistaxis. The treatment of VWD often involves the use of factor replacement therapies, which have significantly evolved in recent years.
When it comes to sepsis, time is of the essence. Research has shown that for each hour that antibiotic administration to sepsis patients is delayed, there is a linear increase in the risk of mortality.
Approximately 1.7 million individuals in the US develop sepsis each year, yet no gold standard exists for the diagnosis of sepsis in a clinical setting. Identification and treatment are determined based on a combination of tests and the clinician’s judgment.
We need your help to grow this newsletter! Please pass along the subscription link to any colleague you think would benefit from hearing about med lab news.